Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus

Although there is no HbA1c threshold for cardiovascular risk, the American Diabetic Association-recommended goal of HbA1c < 7.0% appears to be unacceptably high. To achieve an optimal HbA1c level goal of 6.0% or less, a high dosage of sulfonylureas and insulin would be required; the trade-off wou...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Sun Woo
Formato: Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021108/
https://www.ncbi.nlm.nih.gov/pubmed/21246005
http://dx.doi.org/10.4093/kdj.2010.34.6.331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021108/
https://www.ncbi.nlm.nih.gov/pubmed/21246005
http://dx.doi.org/10.4093/kdj.2010.34.6.331

Ejemplares similares